Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday

Foghorn Therapeutics (NASDAQ:FHTX) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $4.96 million for the quarter.

Foghorn Therapeutics (NASDAQ:FHTX) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.13. The firm had revenue of $2.86 million for the quarter, compared to analyst estimates of $8.56 million. On average, analysts expect Foghorn Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Trading Up 1.9 %

Shares of NASDAQ FHTX opened at $4.24 on Friday. The stock has a market capitalization of $235.79 million, a PE ratio of -2.21 and a beta of 3.16. Foghorn Therapeutics has a twelve month low of $2.94 and a twelve month high of $10.25. The stock has a fifty day simple moving average of $4.05 and a 200-day simple moving average of $5.42.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on FHTX. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Foghorn Therapeutics in a research note on Wednesday. Citigroup initiated coverage on Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set an “outperform” rating on the stock. Citizens Jmp initiated coverage on Foghorn Therapeutics in a report on Wednesday, April 23rd. They issued a “mkt outperform” rating and a $9.00 target price for the company. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Foghorn Therapeutics in a report on Wednesday. Finally, B. Riley assumed coverage on Foghorn Therapeutics in a research note on Thursday, January 30th. They issued a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $12.13.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.